CXCR4 and breast cancer: When combined with eribulin, a chemotherapeutic microtubule inhibitor, a novel CXCL12/CXCR4 antagonist POL5551 reduces metastasis and prolongs survival in mice after resection of the primary breast cancer, compared with single-agent eribulin (161).